↓ Skip to main content

RNA Vaccines

Overview of attention for book
Cover of 'RNA Vaccines'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Introduction to RNA Vaccines.
  3. Altmetric Badge
    Chapter 2 Self-Replicating RNA.
  4. Altmetric Badge
    Chapter 3 Self-Replicating RNA Vaccine Delivery to Dendritic Cells.
  5. Altmetric Badge
    Chapter 4 Plant Expression of Trans-Encapsidated Viral Nanoparticle Vaccines with Animal RNA Replicons.
  6. Altmetric Badge
    Chapter 5 RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA Vaccines.
  7. Altmetric Badge
    Chapter 6 Nucleoside Modified mRNA Vaccines for Infectious Diseases.
  8. Altmetric Badge
    Chapter 7 Generation and Evaluation of Prophylactic mRNA Vaccines Against Allergy.
  9. Altmetric Badge
    Chapter 8 Measuring the Adjuvant Activity of RNA Vaccines.
  10. Altmetric Badge
    Chapter 9 Generation of Immunostimulating 130 nm Protamine-RNA nanoparticles.
  11. Altmetric Badge
    Chapter 10 Electroporation of mRNA as Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.
  12. Altmetric Badge
    Chapter 11 Adjuvant-Enhanced mRNA Vaccines.
  13. Altmetric Badge
    Chapter 12 Enhanced Delivery of DNA or RNA Vaccines by Electroporation.
  14. Altmetric Badge
    Chapter 13 The European Regulatory Environment of RNA-Based Vaccines.
  15. Altmetric Badge
    Chapter 14 Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome.
  16. Altmetric Badge
    Chapter 15 Considerations for Producing mRNA Vaccines for Clinical Trials.
  17. Altmetric Badge
    Chapter 16 Nonclinical Safety Testing of RNA Vaccines.
  18. Altmetric Badge
    Chapter 17 Immunotherapy of Uveal Melanoma: Vaccination Against Cancer.
Attention for Chapter 6: Nucleoside Modified mRNA Vaccines for Infectious Diseases.
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

blogs
1 blog
twitter
9 tweeters
wikipedia
15 Wikipedia pages

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
86 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Nucleoside Modified mRNA Vaccines for Infectious Diseases.
Chapter number 6
Book title
RNA Vaccines
Published in
Methods in molecular biology, January 2017
DOI 10.1007/978-1-4939-6481-9_6
Pubmed ID
Book ISBNs
978-1-4939-6479-6, 978-1-4939-6481-9
Authors

Norbert Pardi, Drew Weissman, Pardi, Norbert, Weissman, Drew

Editors

Thomas Kramps, Knut Elbers

Abstract

In recent years, numerous studies have demonstrated the outstanding abilities of mRNA to elicit potent immune responses against pathogens, making it a viable new platform for vaccine development (reviewed in Weissman, Expert Rev Vaccines 14:265-281, 2015; Sahin et al., Nat Rev Drug Discov 13:759-780, 2014). The incorporation of modified nucleosides in mRNA has many advantages and is currently undergoing a renaissance in the field of therapeutic protein delivery. Its use in a vaccine against infectious diseases has only begun to be described, but offers advantages for the generation of potent and long-lived antibody responses. FPLC purification and substitution of modified nucleosides in the mRNA make it non-inflammatory and highly translatable (Kariko et al., Immunity 23:165-175, 2005; Kariko et al., Mol Ther 16:1833-1840, 2008; Kariko et al., Nucleic Acids Research 39:e142, 2011) that are crucial features for therapeutic relevance. Formulation of the mRNA in lipid nanoparticles (LNPs) protects it from degradation enabling high levels of protein production for extended periods of time (Pardi et al., J Control Release, 2015). Here, we describe a simple vaccination method using LNP-encapsulated 1-methylpseudouridine-containing FPLC purified mRNA in mice. Furthermore, we describe the evaluation of antigen-specific T and B cell responses elicited by this vaccine format.

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 86 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 86 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 15 17%
Student > Bachelor 11 13%
Researcher 10 12%
Student > Master 8 9%
Student > Doctoral Student 5 6%
Other 14 16%
Unknown 23 27%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 17 20%
Agricultural and Biological Sciences 9 10%
Pharmacology, Toxicology and Pharmaceutical Science 8 9%
Immunology and Microbiology 7 8%
Medicine and Dentistry 7 8%
Other 10 12%
Unknown 28 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 November 2021.
All research outputs
#1,893,691
of 22,448,731 outputs
Outputs from Methods in molecular biology
#283
of 12,894 outputs
Outputs of similar age
#45,582
of 424,320 outputs
Outputs of similar age from Methods in molecular biology
#48
of 1,658 outputs
Altmetric has tracked 22,448,731 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,894 research outputs from this source. They receive a mean Attention Score of 3.3. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 424,320 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 1,658 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.